Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BA1
The NM_001366385.1(CARD14):c.2458C>T(p.Arg820Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.47 in 1,612,294 control chromosomes in the GnomAD database, including 183,807 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
CARD14 (HGNC:16446): (caspase recruitment domain family member 14) This gene encodes a caspase recruitment domain-containing protein that is a member of the membrane-associated guanylate kinase (MAGUK) family of proteins. Members of this protein family are scaffold proteins that are involved in a diverse array of cellular processes including cellular adhesion, signal transduction and cell polarity control. This protein has been shown to specifically interact with BCL10, a protein known to function as a positive regulator of cell apoptosis and NF-kappaB activation. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Apr 2012]
Computational evidence support a benign effect (MetaRNN=1.8051267E-4).
BP6
Variant 17-80205094-C-T is Benign according to our data. Variant chr17-80205094-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 402487.We mark this variant Likely_benign, oryginal submissions are: {Likely_pathogenic=1, Benign=8, not_provided=1}. Variant chr17-80205094-C-T is described in Lovd as [Benign].
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.495 is higher than 0.05.
Variant interpreted as Benign and reported on 04-27-2020 by Lab or GTR ID 500031. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. This variant was reported in an individual referred for clinical diagnostic genetic testing. -
Benign, criteria provided, single submitter
not provided
Breakthrough Genomics, Breakthrough Genomics
-
- -
Benign, criteria provided, single submitter
clinical testing
GeneDx
Jul 05, 2018
This variant is associated with the following publications: (PMID: 27706581, 26249641, 31994212, 23905699, 26854129, 30018619, 23143594) -
Pityriasis rubra pilaris Pathogenic:1Benign:1
Likely pathogenic, criteria provided, single submitter
clinical testing
Clinical Genomics, Uppaluri K&H Personalized Medicine Clinic
Feb 21, 2024
CARD14 is a scaffold protein that mediates NF-κB signal transduction in skin keratinocytes. Potent mutations in Card14 have been shown to be associated with familial pustular psoriasis and other cutaneous inflammatory conditions like Pytriasis rubra pilaris. Sufficient evidence is found to confer the association of this particular variant rs11652075 with psoriasis.This variant is found to be a potent moderate impact, deleterious variant with a CADD score of 20.9 and sufficient scientific evidence to support the reported classification. This is found more frequently in psoriasis as per recent evidence as well. -
Benign, criteria provided, single submitter
clinical testing
Genome-Nilou Lab
Jul 14, 2021
- -
not specified Benign:2
Benign, criteria provided, single submitter
clinical testing
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Mar 29, 2016
Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Frequency -
Benign, criteria provided, single submitter
clinical testing
Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan
Nov 12, 2023
This variant is classified as Benign based on local population frequency. This variant was detected in 60% of patients studied by a panel of primary immunodeficiencies. Number of patients: 58. Only high quality variants are reported. -